562 results about "Vaccine Production" patented technology

Disclosed are apparatus and methods for enhancing or improving cell cultures, including cell cultures for the production of monoclonal antibodies, using electromagnetic energy treatment, primarily using light in the near infrared to visible region of the spectrum. The delivery of light energy to a culture, in accordance with preferred embodiments, enhances or improves the cell culture such as by providing for enhanced and accelerated formation of important biological macromolecules, including, but not limited to, antibodies, proteins, collagen, and polysaccharides, and also providing for accelerated cellular replication and an enhancement or prolongation of the life of cells so treated.

The present invention provides a novel avian herpesvirus (NAHV) vector and recombinant vaccines made therefrom that are useful to immunize avian species against Marek's disease, infectious laryngotracheitis and Newcastle disease. Methods of immunizing an avian species against Marek's disease, infectious laryngotracheitis and Newcastle disease are also provided.

The invention is directed to novel live attenuated influenza virus (LAIV) vaccines comprising one or more microRNA (miRNA) Response Element(s) (MRE) within an influenza virus genome. The MREs useful for the present invention can be derived from any miRNA which is highly expressed in influenza-targeted cells of an animal in need of vaccination but are not expressed or are expressed at very low levels in species (e.g., embryonated chicken eggs) or cell lines used for a large-scale vaccine production. This allows efficient vaccine production but renders the vaccine virus susceptible to attenuation in the influenza-targeted cells of vaccinated animals expressing a cognate miRNA.

The invention relates to the field of biotechnology, in particular to a method for rapidly screening the recombinant fowlpox virus by means of a CRISPR/Cas9 system and application thereof. The method comprises the steps of designing an sgRNA (short guide RNA) double-stranded oligonucleotide sequence of a target gene, ligating the sequence with a linearized plasmid vector to obtain an sgRNA expression vector, co-transfecting chicken embryo fibroblasts (CEF) with the sgRNA expression vector, recombinant fowlpox virus plasmids expressing a foreign gene and the fowlpox virus, and conducting purification and verifying the purification effect. By means of the CRISPR/Cas9 method, the number of recombinant fowlpox virus screening generations is reduced to 3-4, the efficiency of vaccine production is greatly improved, operation is easy, and the production cost is reduced.

The present invention provides compositions and methods for generating and cryopreserving dendritic cells with superior functionality in producing stronger signals to T cells, resulting in a more potent DC-based anti-tumor vaccine. The present invention includes mature, antigen loaded DCs activated by Toll-like receptor agonists that induce clinically effective immune responses, preferably when used earlier in the disease process. The DCs of the present invention produce desirable levels of cytokines and chemokines, and further have the capacity to induce apoptosis of tumor cells. The cells can be cryopreserved and thawed for later use, thereby reducing the need for repeated pheresis and elutriation processes during vaccine production. These methods can also be utilized to directly target molecules involved in carcinogenetic signaling pathways and cancer stem cells.

The invention relates to a vaccine production technology in the technical field of biology, in particular to a CHO cell strain which is established by utilizing a gene engineering means and is used for expressing recombinant protein PigFC-pigSCFVE2, and a preparation method and application of the recombinant protein. The recombinant fusion protein PigFC-pigSCFVE2 provided by the invention is A1) or A2) shown as follows, wherein A1) is protein of which the amino acid sequence is as shown in SEQ ID No.2, and A2) is protein which is obtained by substituting, losing and/or adding one or several amino acid residues in the amino acid sequence of the protein of the A1) and has PigFC-pigSCFVE2 activity. A monoclonal cell strain which is obtained through the method and capable of carrying out secretory expression on PigFC-pigSCFVE2 is higher in fusion protein expression quantity, fusion protein obtained through affinity separation and purification of an antibody can be combined with a monoclonal antibody, animals can be immunized, the immunity of a generated neutralizing antibody is higher than that of a present market product, the fusion protein can be used for swine classical fever preventive vaccine, and the production cost and the immunity failure loss can be reduced.

Disclosed are apparatuses and methods for the production of attenuated aseptic parasites in haematophagous insects generally, and production of Plasmodium species sporozoites in Anopheles species mosquitoes specifically; apparatuses and methods for the production of strains of haematophagous insects with desired properties such as hypoallergenicity or hyperinfectivity; methods of producing a parasite strain that is capable of withstanding cyropreservation at temperatures close to freezing; apparatuses and methods for the injection of an attenuated parasite vaccine; production of parasites and haematophagous insects that are free from contamination by unwanted biological agents; apparatuses for the reconstruction of complex parasitic life cycles aseptically to avoid the contamination of the parasite or the insect vector host with unwanted biological agents.

The invention relates generally to the field of virology. More particularly, the present invention relates to methods for determining the permissiveness of a cell for a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, in particular for Porcine Reproductive and Respiratory Syndrome Virus (PRRSV). The invention further provides methods and compositions related to the generation of host cells permissive for a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, in particular for Porcine Reproductive and Respiratory Syndrome Virus (PRRSV). Methods of using said cells thus identified or thus generated, in preparing a culture of a virus that is a member of the family Arteriviridae or Coronaviridae or Asfarviridae, as well as the use of said virus for the purpose of vaccine production or diagnosis, are also provide by the present invention.

The invention discloses an avian influenza virus inactivated vaccine and a preparation method thereof. Adaptive avian influenza viruses are adaptive to screening and domestication of a continuous cell line, and after the viruses are adaptive to cells, the number of the viruses is continuously increased until the viruses are inoculated into a cell culture bottle or a bioreactor to culture. After the obtained culture is inactivated, the obtained culture and mineral oil adjuvant are mixed and emulsified so as to prepare the vaccine. A virus reproduction method for producing an avian vaccine by means of utilizing a large quantity of chicken embryo is omitted, resource consumption is reduced, environmental pollution is decreased, biosafety is guaranteed, cost is lowered, and production efficiency is improved. By the aid of the preparation method, high-potency viruses can be produced to prepare corresponding vaccines, and requirements of fast and high-efficient vaccine production are met.

The invention relates to a method for industrially producing a pseudorabies vaccine by using a bioreactor. The method comprises the following steps of: (1) sterilizing a microcarrier and the bioreactor, inoculating cells for vaccine production, culturing the cells, and after the cells on the microcarrier form a compact monolayer, inoculating pseudorabies virus, and continuously culturing to allow the virus to reproduce; (2) after more than 80 percent of cells are subjected to a cytopathic effect, stopping culturing, and obtaining virus liquid to prepare the pseudorabies vaccine. In the method, the pseudorabies vaccine is produced by culturing the cells in high density by the bioreactor microcarrier culture technology; and compared with the conventional roller bottle production process, the invention has the advantages that: the method has high automation control degree, saves manpower, reduces cost and is small in production land, the production can be monitored in real time, the scale is easy to expand, the produced virus has high titer and small difference among batches, and the product has stable quality and small side effect.

The invention discloses a human vaccine-matched vaccination information acquisition and traceability system, which comprises a vaccine information acquisition device, a vaccination implementer information acquisition device, a vaccination object information acquisition device, a vaccination information bank, a short message service platform, and an information processing system, wherein the vaccine information acquisition device is in charge of acquiring vaccine production and circulation information; the vaccination implementer information acquisition device is used for directly reading and recording the identity information and the occupation information of the vaccination implementer; the vaccination object information acquisition device is used for directly reading and recording the identity information of the vaccination object; the vaccination information bank comprises a server and a database for recording the information of the acquired vaccine, the vaccination implementer and the vaccination object the short message service platform is used for sending vaccine eligibility verification information, and vaccination vaccine type and time type prompt information to the vaccination object and receiving vaccination confirmation information by the vaccination person; and the information processing system is used for being in charge of acquisition, query, matching and storing on human and vaccine information during the vaccination implementation process. The system of the invention has the advantages that the principle is simple; realization is easy; and each vaccine can be ensured to be safely controlled, and the vaccination is ensured to be safe and effective.

The present invention relates to isolated influenza virus strains suitable for increased vaccine production for mammals. The influenza virus strains contain at least one modified influenza protein that results in increased production of the influenza virus from a mammalian host cell, such as a vero cell. The present invention also relates to the vaccines produced from the influenza virus strains. The present invention further relates to isolated modified influenza proteins and isolated nucleic acid molecules that encode for the modified influenza proteins.

The invention discloses application of a baby hamster kidney(BHK)-21 cell serum-free suspension culture technology in foot-and-mouth disease vaccine production, which comprises the following steps of: 1) performing cell recovery; 2) performing reactor culture and cell amplification culture; and 3) inoculating foot-and-mouth disease virus seed venom and collecting the venom. A process for producing foot-and-mouth disease inactivated vaccines by culturing the BHK-21 cells through serum-free suspension culture and a step-by-step cell amplification method make the production period f the foot-and-mouth disease vaccines shortened and yield increased, and ensure stable quality and obvious benefit. The production process reduces the using amount of a culture medium, and the amount of the collected virus liquid is the culture medium consumption amount, while the culture medium consumption amount in a roller bottle production process is 2 times higher than the amount of the collected virus liquid, and bovine serum which is about 5 percent of the culture medium amount is needed.

The invention relates to a preparation method of a novel oil-free adjuvant (adjuvant 605) compound and an application of the novel oil-free adjuvant in veterinary vaccines. The adjuvant prepared by using the method provided by the invention is capable of completely taking the place of mineral oil adjuvants and alumina gel adjuvants for inactivated vaccine production; the adjuvant can be completely absorbed by organisms within short time without residual; the adjuvant is low in side reaction, and capable of improving the safety of vaccines, and simultaneously simplifying the vaccine production process and reducing the vaccine production cost. The adjuvant prepared by using the method provided by the invention can be also taken as live vaccine diluting protection liquid, and has the characteristics of protecting the biological activity of the vaccine antigen, enhancing the immune effect of the vaccine, prolonging the persistent period of the vaccine antibody and the like.

The invention discloses a newly isolated avian adenovirus 4-type HNJZ strain. The microbial preservation number of the newly isolated avian adenovirus 4-type HNJZ strain is CGMCC NO.13385, and the strain has good specificity and immunogenicity, can serve as an inactivated vaccine production strain and an inspection strain and is used for preventing hepatitis-hydropericardium syndromes of poultry. The invention further discloses a vaccine composition prepared from the avian adenovirus 4 type HNJZ strain. The vaccine composition contains the inactivated avian adenovirus 4-type HNJZ strain and pharmaceutically acceptable adjuvant, the vaccine composition has good immunogenicity, high immunity can be generated after immunization, the protection rate is high, prevalence and spread of avian adenoviruses can be effectively prevented, and application prospects are wide.

The invention discloses preparation methods for CHO cell expressed recombinant bovine viral diarrhea virus protein E2 and a subunit vaccine and applications and belongs to the technical fields of animal vaccines and veterinary biologicals. The object of the invention is to provide a preparation method capable of industrially producing the bovine viral diarrhea virus recombinant subunit vaccine ona large scale. The preparation method for the recombinant subunit vaccine, provided by the invention, comprises the following steps: 1) cloning an eukaryotic expression vector containing a protein E2coding gene; 2) transfecting CHO cells, and performing selection, screening and acclimatizing to obtain suspending CHO cell strains, which stably and efficiently express the protein E2; 3) subjectingthe cell strains obtained in the step 2) to fermentation culture, and carrying out purification, so as to obtain recombinant protein E2; and 4) uniformly mixing the recombinant protein E2 and ISA 201VG thoroughly, thereby obtaining the recombinant subunit vaccine. According to the method provided by the invention, target protein can be obtained from cell culture supernatant, the yield reaches upto 500mg/L, the protein purification time is shortened, the vaccine production steps are simplified, and the vaccine production cost is greatly reduced.